Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2025-04-30 Proxy Solicitation & In…
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a 'DEFA14A' filing, which is a Definitive Additional Proxy Solicitation Material under Schedule 14A. It is related to proxy statements and soliciting materials for shareholder meetings. The text explicitly mentions 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and 'Definitive Additional Materials.' This type of filing is used to provide additional information to shareholders to solicit votes, fitting the category of Proxy Solicitation & Information Statement. The document length is short (1053 characters), consistent with a solicitation material rather than a full report. Therefore, the correct classification is PSI (Proxy Solicitation & Information Statement).
2025-04-30 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2025-04-30 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-30 English
FORM PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed pursuant to Schedule 14A under the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on such as election of directors, ratification of auditors, executive compensation advisory vote, and amendments to the incentive plan. It also contains governance information, compensation discussion, and other related materials typically included in proxy statements. The document is not an Annual Report (10-K), nor an earnings release or other financial report. It is not a voting results announcement or a report publication announcement. The presence of detailed proxy solicitation materials and voting instructions clearly identifies this as a Proxy Solicitation & Information Statement filing.
2025-04-18 English
FORM 4
Director's Dealing
2025-03-18 English
FORM 4
Director's Dealing
2025-03-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.